VDPHL01 is an innovative oral drug developed by Veradermics. Unlike traditional treatments, it does not affect the hormonal system, reducing the likelihood of side effects such as decreased libido and erectile dysfunction, which are common among patients taking finasteride.
Scientists emphasize that VDPHL01 works at the molecular level, protecting hair follicles from the effects of DHT without altering hormone levels in the body. This makes it a promising option for men who experience discomfort with current treatment methods.
Sources: Veradermics press briefing (2024-11-05, accessed 22 Oct 2025)
Key facts
- Therapeutic area — androgenetic alopecia (AGA).
- Formulation — once-daily oral tablet (investigational dosage undisclosed).
- Mechanism — non-hormonal; aims to protect follicles from DHT without systemic endocrine changes (detailed pathway under investigation).
- Clinical stage — active Phase 2/3 trial, primary completion planned for 1 Jul 2026 (NCT06724614).
- Regulatory status — not approved, not available for purchase.
- Developer — Veradermics Inc. (USA).
Sources: ClinicalTrials.gov NCT06724614 (accessed 22 Oct 2025); Veradermics pipeline note (2025-03-12).
Who may benefit in future
- Adults with early- to mid-stage AGA seeking a non-hormonal systemic therapy.
- Individuals who discontinued 5-alpha-reductase inhibitors due to sexual or mood-related adverse effects.
- Patients looking to combine oral therapy with topical or procedural approaches (pending safety data).
Source: Expert panel summary, World Congress for Hair Research 2025 (session 4; accessed 22 Oct 2025).
What’s next?
Full efficacy and safety results will become available after the current Phase 2/3 study closes. Follow the detailed timeline on the Clinical Trials page and see comparative data on the Treatment Comparison page.